Lexeo Therapeutics, Inc. (LXEO)
NASDAQ:LXEO
Want to see LXEO full AI Analyst Report?
Top Page
Lexeo Therapeutics, Inc.
(NASDAQ:LXEO)
Select Model
Select Model
Rating:47Neutral
Price Target:
$5.00
▼(-27.64% Downside)
Action:Reiterated
Date:05/21/26
Overall score is weighed down primarily by very weak fundamentals (minimal revenue, large losses, and significant cash burn) and bearish technicals (below key moving averages with negative MACD). Partially offsetting this are low leverage and positive corporate developments (program progress, strengthened cash runway, and leadership/board additions).
Positive Factors
Pivotal program advancement
Progressing LX2006 toward a pivotal SUNRISE-FA2 trial and reporting sustained, statistically significant interim benefits creates a clearer regulatory path and derisks late-stage execution. This supports a multi-quarter to multi-year runway toward potential approval and broader clinical validation.
Negative Factors
High cash burn
Consistently deep negative operating and free cash flow reflects high R&D and development spending and creates ongoing financing dependency. Over multiple quarters this raises dilution risk, constrains discretionary investment, and could force strategic trade-offs if costs outpace funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Pivotal program advancement
Progressing LX2006 toward a pivotal SUNRISE-FA2 trial and reporting sustained, statistically significant interim benefits creates a clearer regulatory path and derisks late-stage execution. This supports a multi-quarter to multi-year runway toward potential approval and broader clinical validation.
Read all positive factors
Lexeo Therapeutics, Inc. (LXEO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$401.25M
Dividend YieldN/A
Average Volume (3M)758.65K
Price to Earnings (P/E)―
Beta (1Y)2.15
Revenue GrowthN/A
EPS Growth56.00%
CountryUS
Employees75
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.45
Shares Outstanding78,521,640
10 Day Avg. Volume928,616
30 Day Avg. Volume758,652
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.16
Price to Sales (P/S)0.00
P/FCF Ratio-5.38
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-616.93
Enterprise Value/Ebitda-3.86
Forecast
1Y Price Target
$18.60Price Target Upside169.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.18
Revenue Forecast (FY)N/A
Lexeo Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia...
How the Company Makes Money
null...
Lexeo Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 654.00K | 1.66M |
| Gross Profit | -546.00K | 0.00 | 0.00 | 0.00 | 654.00K | 1.66M |
| EBITDA | -87.35M | -97.68M | -96.19M | -64.35M | -58.04M | -50.61M |
| Net Income | -87.50M | -99.96M | -98.33M | -66.39M | -59.28M | -50.62M |
Balance Sheet | ||||||
| Total Assets | 250.36M | 268.69M | 146.94M | 139.81M | 97.08M | 136.86M |
| Cash, Cash Equivalents and Short-Term Investments | 71.77M | 181.77M | 121.52M | 121.47M | 77.33M | 135.86M |
| Total Debt | 7.37M | 7.89M | 9.92M | 11.64M | 13.48M | 0.00 |
| Total Liabilities | 18.86M | 22.02M | 30.10M | 26.27M | 210.03M | 192.46M |
| Stockholders Equity | 231.50M | 246.67M | 116.84M | 113.53M | -112.95M | -55.60M |
Cash Flow | ||||||
| Free Cash Flow | -98.42M | -98.96M | -81.63M | -59.66M | -55.46M | -44.37M |
| Operating Cash Flow | -97.99M | -98.56M | -81.15M | -59.50M | -54.56M | -44.18M |
| Investing Cash Flow | -78.39M | -90.25M | -94.08M | -165.00K | -901.00K | -188.00K |
| Financing Cash Flow | 219.24M | 216.79M | 88.78M | 103.79M | 189.00K | 150.86M |
Lexeo Therapeutics, Inc. Technical Analysis
Negative
6.91
Price Trends
5.87
Negative
6.70
Negative
7.15
Negative
Market Momentum
-0.30
Positive
41.90
Neutral
37.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LXEO, the sentiment is Negative. The current price of 6.91 is above the 20-day moving average (MA) of 5.55, above the 50-day MA of 5.87, and below the 200-day MA of 7.15, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 41.90 is Neutral, neither overbought nor oversold. The STOCH value of 37.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LXEO.
Lexeo Therapeutics, Inc. Risk Analysis
Lexeo Therapeutics, Inc. disclosed 75 risk factors in its most recent earnings report. Lexeo Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lexeo Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.67B | -12.86 | -59.27% | ― | -100.00% | -62.96% | |
49 Neutral | $33.49M | -1.10 | -64.17% | ― | -100.00% | 94.65% | |
48 Neutral | $318.45M | -9.07 | -77.09% | ― | ― | -9.22% | |
47 Neutral | $401.25M | -5.77 | -47.48% | ― | ― | 56.00% | |
47 Neutral | $358.40M | -3.24 | -134.14% | ― | ― | -39.31% | |
44 Neutral | $385.80M | -11.02 | -34.82% | ― | ― | 41.21% |
* Healthcare Sector Average
LXEO
Lexeo Therapeutics, Inc.
5.11
2.41
89.26%
TVRD
Tvardi Therapeutics
3.57
-25.52
-87.73%
LRMR
Larimar Therapeutics
3.45
1.58
84.49%
CAPR
Capricor Therapeutics
28.87
18.62
181.66%
BNTC
Benitec Biopharma
11.23
-1.96
-14.86%
DMAC
Diamedica Therapeutics
5.91
1.76
42.41%
Lexeo Therapeutics, Inc. Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresProduct-Related AnnouncementsRegulatory Filings and Compliance
Lexeo Highlights Q1 Progress Advancing Cardiac Gene Therapies
Positive
May 11, 2026
On May 11, 2026, Lexeo Therapeutics reported first-quarter 2026 results and operational progress, highlighting advancement of its LX2006 and LX2020 gene therapy programs and strengthening of its leadership. The company submitted the SUNRISE-FA2 pi...
Business Operations and StrategyExecutive/Board Changes
Lexeo Therapeutics Adds Genomic Medicine Leader to Board
Positive
Apr 30, 2026
On April 28, 2026, Lexeo Therapeutics appointed Dr. Laura Sepp-Lorenzino to its board of directors, with her term running through the 2028 annual meeting of stockholders. She was also named to the Science and Technology Committee, reinforcing the ...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances
Positive
Mar 30, 2026
Lexeo Therapeutics reported fourth-quarter and full-year 2025 results on March 30, 2026, highlighting steady advancement of its cardiac gene therapy pipeline and a strengthened balance sheet. The company ended 2025 with $246.6 million in cash, cas...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.